secwatch.observer — SEC 8-K summary
======================================

Issuer:     Syra Health Corp (SYRA)
CIK:        0001922335
Form:       8-K
Filed at:   2024-03-25T23:59:59+00:00
Accession:  0001493152-24-011142
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Syra Health 2023 revenue $5.5M, net loss $2.94M; projects 64-100% growth in 2024
--------------------------------------------------------------------------------

- FY2023 revenue $5.5M, net loss $(2.94M), vs $5.6M and $(2.12M) in 2022.
- Gross profit margin improved 670 bps to 25.6% from 18.9% in 2022 on mix shift to higher-margin units.
- Adjusted EBITDA loss widened to $(2.8M) from $(2.1M); cash balance $3.3M with no long-term debt.
- Guides FY2024 revenue of $9-$11M (64-100% growth), excluding potential revenue from recent Caduceus federal contract.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1922335/000149315224011142/0001493152-24-011142-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1922335/000149315224011142/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-011142

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer